Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akari TherapeuticsSTU:CLA1 30 Debt-to-EBITDA is -0.04 as of Jun. 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 30/100. Among 314 Biotechnology companies, Akari Therapeutics ranks worse than 318471.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Akari Therapeutics's Debt-to-EBITDA or its related term are showing as below:
STU:CLA1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.17 Med: -0.11 Max: -0.02
Current: -0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of Akari Therapeutics was -0.02. The lowest was -0.17. And the median was -0.11.
STU:CLA1's Debt-to-EBITDA is ranked worse than 100% of 314
companies
in the Biotechnology industry
Industry Median: 1.41
vs STU:CLA1: -0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Akari Therapeutics Debt-to-EBITDA Related Terms
Akari Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Akari Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CLA1 vs MBRX, INTI, TPST: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Akari Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Akari Therapeutics (STU:CLA1) has a Debt-to-EBITDA of -0.04 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Akari Therapeutics. According to the industry distribution chart, Akari Therapeutics ranks #999999 out of 314 companies in the Biotechnology industry.
Is Akari Therapeutics' Debt-to-EBITDA too high?
Akari Therapeutics' current Debt-to-EBITDA is -0.04. Based on the distribution chart, Akari Therapeutics ranks #999999 out of 314 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Akari Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Debt-to-EBITDA compare to MBRX and INTI?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #999999 out of 314 companies for Debt-to-EBITDA. This places Akari Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.41, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Akari Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current Debt-to-EBITDA of -0.04. The current Debt-to-EBITDA is -0.04. Akari Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current Debt-to-EBITDA is -0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
30GF Score
Get the complete analysis for STU:CLA1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLA1 has been successfully added to your 
